M&A / Deals Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide Pharmaceutical Business ReviewThe agreement covers Hanmi's candidate that uses its LAPSCOVERY long-acting platform technology.Metabolic & GLP-1Read full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaceutical Business Review The agreement covers Hanmi’s candidate that uses its LAPSCOVERY long-acting platform technology. Metabolic & GLP-1 Read full story Post navigation Previous: FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapyNext: ASCO: Summit reached with China lung data but new climb begins to prove global benefit Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
